- Favorable Immunogenicity Profile
- Meets WHO Standard for Vaccine Quality, Safety and Efficacy
- Covers the Most Prevalent Serotypes in Iran
- A Tailored PCV* with 6A, 19A Serotypes
- Similar Coverage to other PCVs in High Diseases Burden Countries
*PCV, Pneumococcal Conjugate Vaccine
Dosage and Administration:
Vaccination Schedule for Infants and Toddlers
| Dosage Schedules | Dose 1 a, b | Dose 2 b | Dose 3 b | Dose 4 c, d |
|---|---|---|---|---|
| 3p+1 | 6 weeks | 10 weeks | 14 weeks | 9-10 months or 12-15 months |
| 3p+0 | 6 weeks | 10 weeks | 14 weeks | - |
| 2p+1 | 6 weeks | - | 14 weeks | 9-18 months |
| a. Dose 1 may be given as early as 6 weeks or at 2 months of age. b. The recommended dosing interval is 4 to 8 weeks. c. A booster (fourth) dose is recommended at least 6 months after the last primary dose and may be given from the age of 9 months onwards (preferably between 12 and 15 months of age). d. A booster dose is recommended at the age of 9-18 months of age. |
||||
Vaccination Schedule for Unvaccinated Children 7 Months of Age Through 2 Years of Age
| Age at First Dose | Total Number of 0.5 ml Doses |
|---|---|
| 7-11 months of age | 3 a |
| 12-24 months of age | 2 b |
| a. The vaccination schedule consists of two primary doses of 0.5 ml with an interval of at least 1 month between doses. A booster (third) dose is recommended in the second year of life with an interval of at least 2 months after the last primary dose. b. The vaccination schedule consists of two doses of 0.5 ml with an interval of at least 2 months between doses. |
|
References:
2. https://extranet.who.int/pqweb/vaccines/list-prequalified-vaccines
3. Pneumosil Package Insert, Revision date: 03/2023
4. Infect Disord Drug Targets. 2021; 21(2): 304-310
5. Eur J Clin Microbiol Infect Dis. 2020; 39(12):2257-2267.
Pneumococcal Disease
Pneumococcal disease is a serious infection caused by Streptococcus pneumoniae bacteria that can lead to [...]
26
Jul
Jul